KLP Kapitalforvaltning AS Makes New Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

KLP Kapitalforvaltning AS purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,300 shares of the company's stock, valued at approximately $2,093,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. R Squared Ltd purchased a new stake in Medpace in the fourth quarter worth $30,000. SBI Securities Co. Ltd. purchased a new position in Medpace in the 4th quarter worth about $31,000. Jones Financial Companies Lllp lifted its holdings in Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after buying an additional 110 shares in the last quarter. Lindbrook Capital LLC grew its stake in Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after acquiring an additional 29 shares in the last quarter. Finally, True Wealth Design LLC increased its position in shares of Medpace by 16,800.0% during the third quarter. True Wealth Design LLC now owns 169 shares of the company's stock worth $56,000 after acquiring an additional 168 shares during the period. 77.98% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on MEDP shares. Leerink Partners began coverage on Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 price objective on the stock. Leerink Partnrs raised Medpace to a "hold" rating in a research report on Monday, March 24th. Finally, Robert W. Baird raised their price target on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $376.30.

Remove Ads

Medpace Stock Down 2.3 %

Shares of NASDAQ MEDP traded down $6.96 during trading hours on Tuesday, hitting $297.73. 612,865 shares of the stock were exchanged, compared to its average volume of 301,598. Medpace Holdings, Inc. has a 12 month low of $289.01 and a 12 month high of $459.77. The firm has a fifty day moving average price of $334.26 and a 200-day moving average price of $338.52. The company has a market cap of $9.07 billion, a PE ratio of 23.57, a PEG ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.